Abstract Library

#3026 IMP3 and Ki-67-Factors of Poor Clinical Outcome in Neuroendocrine Tumors of the Lung

Introduction: Insulin- like growth factor-II messenger RNA- binding protein- 3 (IMP3) is often detected in malignant neoplasm of different sites. Ki-67 proliferative index, although helpful in diagnosing neuroendocrine tumours of lung, has not been recognised as prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bełz A, Stęplewska K, Głogowska- Szeląg J,

Keywords: carcinoid, IMP3, Ki-67, neuroendocrine,

#2050 Finding the Ways to Determine the Prognosis of Pulmonary Carcinoids with Certain Genes/Markers in Pakistan

Introduction: Pulmonary neuroendocrine tumors are classified into four subtypes from well differentiated to poorly differentiated high grade large cell neuroendocrine carcinomas. Because of the difficult histological classification and a cancer free period following surgery, it is often difficult to predict certain prognostic factors.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fatima A

Authors: Fatima A, Zaidi S,

Keywords: prognostic markers, CD44, OTP, genes regulation, cancer prognosis,

#1492 Prospective Validation of Prognostic Score in High-Grade Gastrointestinal Neuroendocrine Carcinomas (GI-NECs)

Introduction: Prognostic markers for risk-stratification of GI-NECs are lacking.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lamarca A

Authors: Lamarca A, Barriuso J, McNamara M, Hubner R, Valle J,

Keywords: NEC, score, overall survival, high grade, prognostic,

#1273 Tissue Prognostic Markers in Pancreatic Neuroendocrine Tumours

Introduction: Pancreatic neuroendocrine tumours (pNETs) are a rare, heterogeneous class of neoplasms, with a rising incidence. Prognosis is variable with 5-year survival as low as 16% in inoperable tumours.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Dunbar J

Authors: Dunbar J, Tod J, Horne J, Armstrong T, Cave J,

Keywords: Pancreatic, microenvironment, prognosis,

#1009 Streptozotocin-Based Chemotherapy is Still Alive in Patients with Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival

Introduction: Chemotherapy with Streptozotocin (STZ) and 5-FU or Doxorubicin (Doc) represents a standard of care for patients with well-differentiated metastatic neuroendocrine neoplasms, especially for the pancreas (PNENs). However, data to identify predictive and prognostic markers are limited.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Krug S, Boch M, Rinke A, Müller D, König A,

Keywords: streptozotocin, NEN, 5-fluorouracil, Doc,